HC Wainwright Has Bearish Forecast for DNLI FY2027 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at HC Wainwright reduced their FY2027 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research note issued on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $1.68 for the year, down from their previous estimate of $1.69. HC Wainwright has a “Buy” rating and a $90.00 price target on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.53) per share.

Other equities analysts have also recently issued research reports about the company. Citigroup raised their price target on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Wedbush dropped their target price on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America boosted their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, JPMorgan Chase & Co. dropped their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $38.90.

Denali Therapeutics Price Performance

NASDAQ DNLI opened at $31.35 on Friday. The stock has a market capitalization of $4.51 billion, a PE ratio of -11.36 and a beta of 1.40. The business has a 50 day simple moving average of $27.81 and a two-hundred day simple moving average of $23.56. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $32.13.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the firm posted ($0.72) earnings per share.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the sale, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares in the company, valued at $844,656.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in shares of Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after buying an additional 1,847 shares during the last quarter. CWM LLC raised its holdings in Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after purchasing an additional 654 shares during the period. Quest Partners LLC acquired a new position in Denali Therapeutics in the 3rd quarter worth about $73,000. Headlands Technologies LLC acquired a new position in Denali Therapeutics in the 1st quarter worth about $88,000. Finally, Assetmark Inc. raised its holdings in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.